As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

Only 6 percent of patients carried a concerning DPYD variant, but nearly two-thirds of them were later hospitalized after ...

Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

Within weeks of treating patients with CER-1236, the company hopes to start learning about its safety profile and gauge efficacy markers.

The partners further aim to raise awareness and increase early diagnosis of BAG3-associated dilated cardiomyopathy.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

The Australian company is betting the radionuclide could be an option for patients with HER2-expressing solid tumors who can't tolerate other treatments.

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

The French company is designing a Phase IIb program to validate the biomarker, which could identify the 30 percent of patients likely to respond to the antibody.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...